-
公开(公告)号：US20240293364A1
公开(公告)日：2024-09-05
申请号：US18548522
申请日：2022-03-04
IPC分类号： A61K31/4035 , A61K31/502 , A61K31/5025 , A61P35/00 , G01N33/574
CPC分类号： A61K31/4035 , A61K31/502 , A61K31/5025 , A61P35/00 , G01N33/57484 , G01N2333/9108
摘要： The invention provides DNA damage response (DDR) pathway genes and their gene products as biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more DDR pathway biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. In particular, the DDR pathway comprises one or more genes from: the homologous recombination repair (HRR) pathway; the non-homologous end joining (NHEJ) pathway; the mismatch repair (MMR) pathway; the Fanconi
-
公开(公告)号：US20240261280A1
公开(公告)日：2024-08-08
申请号：US18631828
申请日：2024-04-10
IPC分类号： A61K31/496 , A61K9/00 , A61K9/19 , A61K31/497 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/38
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/19 , A61K31/497 , A61K47/02 , A61K47/10 , A61K47/38 , A61K47/26
摘要： A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
-
公开(公告)号：US12048683B2
公开(公告)日：2024-07-30
申请号：US17228374
申请日：2021-04-12
IPC分类号： A61K31/353 , A23L29/00 , A23L29/30 , A61K31/7048
CPC分类号： A61K31/353 , A23L29/035 , A23L29/30 , A61K31/7048
摘要： The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.
-
公开(公告)号：US12048672B2
公开(公告)日：2024-07-30
申请号：US16611650
申请日：2018-05-01
摘要： Provided is packaged medicine capable of inhibiting deterioration of electrodes over a long period of time and reliably transmitting a signal after ingestion even when a long period of time has elapsed since production to ingestion. The packaged medicine includes a solid medicine including drug powder and a micro-device, a container provided with a solid medicine accommodating space accommodating the solid medicine therein, and inert gas encapsulated in the solid medicine accommodating space. The micro-device includes two electrodes with mutually different ionization tendencies and a transmitter operable to transmit a signal using electromotive force generated when the electrodes come in contact with electrolyte.
-
5.发明公开公开(公告)号：US20240215867A1
公开(公告)日：2024-07-04
申请号：US18407397
申请日：2024-01-08
发明人： Robert AZEVEDO , Neraj P. BOBRA , Aditya DUA , Ronny X. LI , William A. WEEKS
CPC分类号： A61B5/1118 , A61B5/0002 , A61B5/073 , A61B5/318 , A61B5/6801 , A61B5/6861 , A61B5/725 , A61B5/7282 , G01C22/006 , G16H20/30 , G16H40/67 , A61B2562/0219
摘要： A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.
-
公开(公告)号：US20240158380A1
公开(公告)日：2024-05-16
申请号：US18546602
申请日：2022-02-16
发明人： Naoki Kamada , Motoyasu YOSHIMURA , Mariko KIMOTO
IPC分类号： C07D409/14 , A61K9/00 , A61K9/14 , A61K31/496 , A61K47/12
CPC分类号： C07D409/14 , A61K9/0053 , A61K9/146 , A61K31/496 , A61K47/12
摘要： Provided are an amorphous solid dispersion containing compound (I), an amorphous form containing compound (I) and an organic acid, an amorphous solid dispersion containing the amorphous form, a pharmaceutical composition containing the amorphous form or the amorphous solid dispersion, and preparation methods for these.
-
公开(公告)号：US11950615B2
公开(公告)日：2024-04-09
申请号：US17523683
申请日：2021-11-10
发明人： Lawrence Arne , Mark Zdeblick , Aditya Dua , George Savage , Robert Leichner , Jafar Shenasa , Patricia Johnson , Raymond Schmidt , Zahedeh Hatamkhany , Veeraperumanallu Muralidharan
CPC分类号： A23L33/10 , A23L33/00 , A23L35/00 , A23P20/10 , A23P20/19 , G06K7/10366 , G06K19/0717 , G06K19/0723 , H04B5/0031 , H04B5/0062 , A23V2002/00
摘要： An apparatus includes a food product, at least one ingestible device associated with the food product to communicate information and at least one coating material surrounding the at least one ingestible device is disclosed. The ingestible device is associated with an ingestible medication to be ingested in conjunction with the food product. The coating is configured to release the at least one ingestible device upon the occurrence of an event.
-
公开(公告)号：US20240076275A1
公开(公告)日：2024-03-07
申请号：US18498894
申请日：2023-10-31
发明人： Naohiko Kanai , Takayuki Yasutomi , Ryosuke Hirota
IPC分类号： C07D263/32
CPC分类号： C07D263/32 , C07B2200/13
摘要： Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
wherein the crystal has peaks at diffraction angles)2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuKα characteristic X-rays.-
公开(公告)号：US20230405037A1
公开(公告)日：2023-12-21
申请号：US18250674
申请日：2021-10-27
发明人： Kim-Hien Dao , Harold Keer , Aram Oganesian
IPC分类号： A61K31/7068 , A61K31/706 , A61K31/635 , A61P35/02 , A61K9/00
CPC分类号： A61K31/7068 , A61K31/706 , A61K31/635 , A61P35/02 , A61K9/0053
摘要： Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.
-
公开(公告)号：US20230381194A1
公开(公告)日：2023-11-30
申请号：US18363848
申请日：2023-08-02
发明人： Akitsuna AKAGI , Kai SUZUKI , Atsuya NAKAMURA , Toru NISHIBAYASHI
CPC分类号： A61K31/55 , A61K9/1652 , A61K9/0095 , A61K9/0053 , A61K9/10 , A61K47/38 , A61K47/26
摘要： This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
-
-
-
-
-
-
-
-
-
搜索结果
614 条记录 (耗时 0.044 秒)
